Morphological subtypes of ovarian carcinoma: a ... - BPA Pathology

More documents

Recommendations

Info

SUBTYPES OF OVARIAN CARCINOMA 4317. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ,Ronnett BM. The histologic type and stage distribution of ovariancarcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23:41–4.8. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type inlow-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol2010; 29: 203–11.9. Koonings PP, Campbell K, Mishell Dr, et al. Relative frequency ofprimary ovarian neoplasms: a ten year review. Obstet Gynecol 1989;74: 921–6.10. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic valueof histologic type and grade in early epithelial ovarian cancer. Int JGynecol Cancer 1993; 3: 72–9.11. Baak JP, Langley FA, Talerman A, Delemarre JF. Interpathologist andintrapathologist disagreement in ovarian tumor grading and typing. AnalQuant Cytol Histol 1986; 8: 354–7.12. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibilityof the World Health Organization classification of common ovariancancers. With emphasis on methodology. Arch Pathol Lab Med 1987;111: 819–29.13. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathologicalevaluation in epithelial ovarian carcinoma. Clinical implications. APMIS1991; 99: 353–8.14. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement inhistological classification of ovarian tumors in Japan. Gynecol Oncol1996; 54: 54–8.15. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphologicaleffects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002; 55:27–31.16. Miller K, Price JH, Dobbs SP, et al. An immunohistochemical andmorphological analysis of post-chemotherapy ovarian carcinoma. J ClinPathol 2008; 61: 652–7.17. Silverberg SG. Histopathologic grading of ovarian carcinoma: a reviewand proposal. Int J Gynecol Pathol 2000; 19: 7–15.18. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of auniversal grading system for ovarian epithelial carcinoma. I. Prognosticsignificance of histopathologic features – problems involved in thearchitectural grading system. Gynecol Oncol 1998; 70: 2–12.19. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of auniversal grading system for ovarian epithelial carcinoma: testing of aproponed system in a series of 461 patients with uniform treatment andfollow-up. Cancer 1998; 82: 893–901.20. Wilkinson N, McCluggage WG. Datasets for the HistopathologicalReporting of Neoplasms of the Ovaries and Fallopian Tubes and PrimaryCarcinomas of the Peritoneum. London: Royal College of Pathologists,July 2008.21. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis:the value of mutation analysis in the KRAS and BRAF genes.J Pathol 2004; 203: 617–9.22. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways inovarian serous carcinoma. Am J Pathol 2002; 160: 1223–8.23. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-rassegregates ovarian serous carcinomas into two types: invasive MPSC(low-grade tumor) and conventional serous carcinoma. Int J GynecolPathol 2003; 22: 37–41.24. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separateovarian serous borderline tumors and low and high grade carcinomas andprovide support for a new model of ovarian carcinogenesis: a mutationalanalysis with immunohistochemical correlation. Am J Surg Pathol 2005;29: 218–24.25. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRASprecede the development of ovarian serous borderline tumors. Can Res2004; 64: 6915–8.26. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms,BRAF, but not KRAS, mutation are restricted to low-grade seroustumours. J Pathol 2004; 202: 336–40.27. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-gradeserous carcinoma: pathogenesis, clinicopathologic and molecular biologicfeatures, and diagnostic problems. Adv Anat Pathol 2009; 16: 267–82.28. McCluggage WG. The pathology of and controversial aspects of ovarianborderline tumours. Curr Opin Oncol 2010; 22: 462–72.29. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors ofthe ovary into benign and malignant types. A clinicopathologic study of 65advanced stage cases. Am J Surg Pathol 1996; 20: 1331–45.30. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of thefimbria and pelvic serous carcinoma: Evidence for a causal relationship.Am J Surg Pathol 2007; 31: 161–9.31. Lee Y, Medeiros F, Mindelberger D, et al. Advances in the recognition oftubal intraepithelial carcinoma: applications to cancer screening and thepathogenesis of ovarian cancer. Adv Anat Pathol 2006; 13: 1–7.32. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site forearly adenocarcinoma in women with familial ovarian cancer syndrome.Am J Surg Pathol 2007; 30: 230–6.33. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine)serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407–16.34. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serouscarcinoma that originates in the distal fallopian tube. J Pathol 2007;211: 26–35.35. Herrington CS, McCluggage WG. The emerging role of the distalfallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010;220: 5–6.36. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinomausing a two-tier system. Am J Surg Pathol 2004; 28: 496–504.37. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobservervariability of a two-tier system for grading ovarian serous carcinoma. Am JSurg Pathol 2007; 31: 1168–74.38. Dehari R, Kurman RJ, Logani S, et al. The development of high-gradeserous carcinoma from atypical proliferative (borderline) serous tumorsand low-grade micropapillary serous carcinoma: a morphologic andmolecular genetic analysis. Am J Surg Pathol 2007; 31: 1007–12.39. Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinomawith emphasis on the nonepitheliallined spaces pattern of invasionand the disorganised orphan papillae. Int J Gynecol Pathol 2010; 29: 507–12.40. O’Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serouscarcinoma exhibits significantly higher p16 expression than low-gradeserous carcinoma and serous borderline tumour. Histopathology 2007; 50:773–9.41. O’Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. Animmunohistochemical comparison between low-grade and high-gradeovarian serous carcinomas. Significantly higher expression of p53,MIB1, bcl2, her-2/neu and C-KIT in high-grade neoplasms. Am J SurgPathol 2005; 29: 1034–41.42. Kobel M, Reuss A, Du Bois A, et al. The biological and clinical value ofp53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222: 191–8.43. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations inTP53 are ubiquitous in high grade serous carcinomas of the ovary. J Pathol2010; 221: 49–56.44. Gershenson DM, Sun CC, Lu KH, et al. Clinical behaviour of stage II-IVlow-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108: 361–8.45. Folkins A, Jarboe E, Saleemuddin A, et al. A candidate precursor to pelvicserous cancer (p53 signature) and its prevalence in ovaries and fallopiantubes from women with BRCA mutations. Gynecol Oncol 2008; 109:168–73.46. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol2005; 24: 4–25.47. Lerwill MF, Young RH. Mucinous tumours of the ovary. Diagn Histopathol2008; 14: 366–87.48. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderlineovarian tumors: points of general agreement and persistent controversiesregarding nomenculature, diagnostic criteria, and behaviour. Hum Pathol2004; 35: 959–60.49. Lee KR, Young RH. The distinction between primary and secondarymucinous carcinomas of the ovary: gross and histologic findings in50 cases. Am J Surg Pathol 2003; 27: 281–92.50. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinousadenocarcinomas in the ovary: incidence in routine practice with a newapproach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27:985–93.51. Lewis MR, Deavers MT, Silva EG, Malpica A. Ovarian involvement bymetastatic colorectal adenocarcinoma: still a diagnostic challenge. Am JSurg Pathol 2006; 30: 177–84.52. McCluggage WG, Wilkinson N. Metastatic neoplasms involving theovary: a review with an emphasis on morphological and immunohistochemicalfeatures. Histopathology 2005; 47: 231–47.53. Berezowski K, Stasny JF, Kornstein MJ. Cytokeratins 7 and 20 andcarcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol1996; 9: 1040–4.54. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemicaldifferentiation between primary adenocarcinomas of theovary and ovarian metastases of colon and breast origin. Comparisonbetween a statistical and intuitive approach. J Clin Pathol 1999; 52: 283–90.55. Park SO, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 inprimary carcinomas of the stomach and colorectum and their value in thedifferential diagnosis of metastatic carcinomas to the ovary. Hum Pathol2002; 33: 1078–85.56. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression ofCDX2 in primary ovarian mucinous tumors and metastatic mucinousCopyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
432 MCCLUGGAGE Pathology (2011), 43(5), Augustcarcinomas involving the ovary: comparison with CK20 and correlationwith coordinate expression of CK7. Mod Pathol 2006; 19: 1421–8.57. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary andsecondary mucinous tumors of the ovary: analysis of coordinate immunohistochemicalexpression profiles and staining distribution in 179 cases.Am J Surg Pathol 2006; 30: 1130–9.58. Fragetta F, Pelosi G, Cafici A, et al. CDX2 immunoreactivity in primaryand metastatic ovarian mucinous tumours. Virchows Arch 2003; 443: 782–6.59. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemicalmarkers expressed in colonic adenocarcinoma to distinguish primaryovarian tumors from metastatic colorectal carcinoma. Mod Pathol2005; 18: 19–25.60. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 indistinguishing between primary and secondary (intestinal) mucinousovarian carcinoma: an immunohistochemical comparison of 43 cases.Appl Immunohistochem Mol Morphol 2004; 12: 127–31.61. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritonealadenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologicanalysis of 109 cases with emphasis on distinguishing pathologicfeatures, site of origin, prognosis and relationship to ‘pseudomyxomaperitonei’. Am J Surg Pathol 1995; 19: 1390–408.62. Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 insimultaneous mucinous tumors of the ovary and appendix. Mod Pathol1995; 8: 573–6.63. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemicalevidence supporting the appendiceal origin of pseudomyxoma peritoneiin women. Int J Gynecol Pathol 1997; 16: 1–9.64. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associatedwith mature cystic teratomas: morphologic and immunohistochemicalanalysis identifies a subset of potential teratomatous origin that sharesfeatures of lower gastrointestinal tract mucinous tumors more commonlyencountered as secondary tumors in the ovary. Am J Surg Pathol 2007; 31:854–69.65. Tabrizi AD, Kalloger SE, Kobel M, et al. Primary ovarian mucinouscarcinoma of intestinal type: significance of pattern of invasion andimmunohistochemical expression profile in a series of 31 cases. Int JGynecol Pathol 2010; 29: 99–107.66. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinousborderline tumors: are we ready for a nomenculature change? Int JGynecol Pathol 2010; 29: 108–12.67. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequentlyexpress markers of gastric, intestinal and pancreaticobiliary epithelialcells. Cancer 1992; 69: 2131–42.68. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderlinetumors of the ovary: a clinicopathologic analysis of 31 cases. Am J SurgPathol 2004; 28: 1311–8.69. Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas ofmullerian (endocervical-like) type: a clinicopathologic analysis of fourcases of an uncommon variant associated with endometriosis. Int JGynecol Pathol 2003; 22: 42–51.70. Provenza C, Young RH, Prat J. Anaplastic carcinoma in mucinous ovariantumors: a clinicopathologic study of 34 cases emphasizing the crucialimpact of stage on prognosis, their histologic spectrum, and overlap withsarcomalike mural nodules. Am J Surg Pathol 2008; 32: 383–9.71. Baergen RN, Rutgers J. Mural nodules in common epithelial tumors of theovary. Int J Gynecol Pathol 1994; 13: 62–72.72. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative(borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like)types are immunophenotypically distinctive. Int J GynecolPathol 2006; 25: 83–9.73. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Immunohistochemistryfor estrogen and progesterone receptors in the distinction ofprimary and metastatic mucinous tumors in the ovary: an analysis of 124cases. Mod Pathol 2006; 19: 97–105.74. Kelly P, Archbold P, Price JH, Cardwell C, McCluggage WG. SerumCA19.9 levels are commonly elevated in primary ovarian mucinoustumours but cannot be used to predict the histological subtype. J ClinPathol 2010; 63: 169–73.75. Scott M, McCluggage WG. Current concepts in ovarian epithelial tumorigenesis:correlation between morphological and molecular data. HistolHistopathol 2006; 21: 81–92.76. Cantrecasas M, Villaneuva A, Matias-Guiu X, Prat J. K-ras mutations inmucinous ovarian tumors: a clinicopathologic and molecular study of 95cases. Cancer 1997; 70: 1581–6.77. Gemignani ML, Schlaerth AC, Bogomolnly F, et al. Role of KRAS andBRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol2003; 90: 378–81.78. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis:frequency and comparison of ovarian and extraovarian types. Int JGynecol Pathol 2001; 20: 133–9.79. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative(borderline) tumors and well-differentiated endometrioid adenocarcinomasof the ovary. Am J Surg Pathol 2000; 24: 1465–79.80. Zaino RJ. Synchronous carcinomas of the uterine corpus and ovary.Gynecol Oncol 1984; 19: 329–35.81. Tornos C, Silva EG, Ordonez NG, Gershenson DM, Young RH, Scully RE.Endometrioid carcinoma of the ovary with a prominent spindle-cellcomponent, a source of diagnostic confusion. A report of 14 cases. AmJ Surg Pathol 1995; 19: 1343–53.82. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioidproliferations of the uterus and ovary consistently express the intestinaltranscription factor CDX2. Histopathology 2008; 53: 156–65.83. Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations inendometrioid carcinomas of the ovary: similar frequency of beta-cateninabnormalities but lower rate of microsatellite instability and PTENalterations than in uterine endometrioid carcinomas. Hum Pathol 2004;35: 1360–8.84. Brachtel EF, Sánchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J,Oliva E. Distinct molecular alterations in complex endometrial hyperplasia(CEH) with and without immature squamous metaplasia (squamousmorules). Am J Surg Pathol 2009; 29: 1322–9.85. DeLair D, Oliva E, Koble M, et al. Morphologic spectrum of immunohistochemicallycharacterized clear cell carcinoma of the ovary: a study of155 cases. Am J Surg Pathol 2011; 35: 36–44.86. Sangoi AR, Soslow RA, Teng NN, Longacre TA. Ovarian clear cellcarcinoma with papillary features: a potential mimic of serous tumorof low malignant potential. Am J Surg Pathol 2008; 32: 269–74.87. Tan DS, Kaye S. Ovarian clear cell carcinoma: a continuing enigma. J ClinPathol 2007; 60: 355–60.88. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations inendometriosis-associated ovarian carcinomas. N Eng J Med 2010; 363:1532–43.89. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: amorphologic study with emphasis on differential diagnosis. Am J SurgPathol 2004; 28: 453–63.90. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors withputative transitional cell (urothelial) differentiation using novel urothelialmarkers: histogenetic and diagnostic implications. Am J Surg Pathol 2003;27: 1434–41.91. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of theendometrium: a review. Pathology 2007; 39: 134–8.92. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinomacell type is highly reproducible: a transcanadian study. Am J Surg Pathol2010; 34: 984–93.93. McCluggage WG. WT1 is of value in ascertaining the site of origin ofserous carcinomas within the female genital tract. Int J Gynecol Pathol2004; 23: 97–9.94. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemicaldetection of the Wilms’ tumor gene (WT1) in epithelial ovarian tumors. IntJ Gynecol Pathol 2000; 19: 158–63.95. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists indistinguishing ovarian from uterine serous carcinoma and in distinguishingbetween serous and endometrioid ovarian carcinoma. Histopathology2004; 44: 109–15.96. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillaryserous carcinomas is different from ovarian serous carcinomas. Am J ClinPathol 2002; 117: 541–5.97. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkerscan reliably distinguish between clear cell and high-grade serous carcinomaof the ovary. Am J Surg Pathol 2009; 33: 14–21.98. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O.Immunohistochemical detection of hepatocyte nuclear factor 1beta inovarian and endometrial clear-cell adenocarcinomas and nonneoplasticendometrium. Hum Pathol 2007; 38: 1074–80.99. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomasor metaplastic carcinomas? J Clin Pathol 2002; 55: 321–5.100. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mulleriantumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002; 12: 687–90.Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
Page 1 and 2: Pathology (August 2011) 43(5), pp.
Page 3 and 4: 422 MCCLUGGAGE Pathology (2011), 43
Page 11: 430 MCCLUGGAGE Pathology (2011), 43

Morphological subtypes of ovarian carcinoma: a ... - BPA Pathology

Create successful ePaper yourself

Delete template?

Save as template?